Management of prostate cancer

Advanced Radiation Centers of New York Pioneers the First Commercial U.S. Implantation of a Biodegradable Balloon Spacer That Will Revolutionize Radiation Therapy for Prostate Cancer

Retrieved on: 
Thursday, November 2, 2023
Surgery, Men, Medical Devices, General Health, Hospitals, Science, Medical Supplies, Consumer, Clinical Trials, FDA, Biotechnology, Health, Other Science, Research, Other Health, Radiology, Oncology, Solaris, American Cancer Society, Radiation therapy, IMP, Management of prostate cancer, Lung cancer, Prostate cancer, Urology, Multimedia, Death, National Directorate for Migration (Argentina), Rectum, Risk, Radiation, Collateral damage, Safety, ARC, Patient, Prostate, Medical device, Medical imaging

Prostate cancer patients treated at Advanced Radiation Centers of New York (ARC) became the first in the United States to benefit from the implantation of a novel biodegradable rectal spacer – The BioProtect Balloon Implant System.

Key Points: 
  • Prostate cancer patients treated at Advanced Radiation Centers of New York (ARC) became the first in the United States to benefit from the implantation of a novel biodegradable rectal spacer – The BioProtect Balloon Implant System.
  • Now, rather than a gel, the novel biodegradable pre-formed saline-filled BioProtect Balloon® can create nearly double the protective space between the prostate and rectum during radiation therapy.
  • There are 288,300 new cases of prostate cancer a year in the United States and 34,700 deaths from prostate cancer, according to the American Cancer Society.
  • Thomas Schmidt and other men who are initial recipients of the BioProtect Balloon Spacer have non-metastatic and potentially curable prostate cancers.

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Retrieved on: 
Tuesday, October 31, 2023
American Cancer Society, RT, Patent, Biomarker, Management of prostate cancer, Shuttle, Georgetown University, SBIR, Intellectual property, Prostate cancer, Surveillance, Aggression, Database, Risk, SEER, National Cancer Institute, Bangladesh Technical Education Board, NIH, Cancer, IP, Patient, Failure, Pharmaceutical industry, Medical imaging, Epidemiology

ROCKVILLE, Md., Oct. 31, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered into an exclusive agreement to license certain intellectual property (IP) from Georgetown University to advance Shuttle Pharma's predictive biomarker program for prostate cancer.

Key Points: 
  • ROCKVILLE, Md., Oct. 31, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered into an exclusive agreement to license certain intellectual property (IP) from Georgetown University to advance Shuttle Pharma's predictive biomarker program for prostate cancer.
  • Anatoly Dritschilo, M.D., CEO of Shuttle Pharma, commented, "Prostate cancers vary in their aggressiveness and in their responses to treatment.
  • The American Cancer Society estimates that 1 in 8 men will be diagnosed with prostate cancer during his lifetime.
  • Dr. Dritschilo expanded, "Our mission is to accelerate investigation of the prostate cancer metabolite-based predictive assay to improve outcomes of radiation therapy.

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

Retrieved on: 
Wednesday, October 11, 2023
Doctor of Philosophy, SOC, Management of prostate cancer, Vaccine, Interleukin 10, Gamma ray, Trial of the century, Cell, Toxicity, Interleukin 12, Infection, International Cytokine & Interferon Society, Safety, National Cancer Institute, Early Prostate Cancer (clinical programme), Interim, Administration, Interleukin, TTY, Cytokine, Docetaxel, DLT, CD8, Head, Research, Clinical trial, Fourth grade, PSA, Bangladesh Technical Education Board, PDSB, Prostate cancer, Biotechnology, CD4, Patient, MD

Decrease in prostate specific antigen (PSA) levels was seen in all patients at all three tested doses of PDS0301.

Key Points: 
  • Decrease in prostate specific antigen (PSA) levels was seen in all patients at all three tested doses of PDS0301.
  • Data to be presented by National Cancer Institute as an oral presentation at Cytokines 2023.
  • While all doses of PDS0301 were well-tolerated, the 12.0 mcg/kg dose of PDS0301 with chemotherapy provided the best combination of immune response and tolerability.
  • Interim data highlights to be presented at Cytokines 2023 include:
    All doses of the combination were well-tolerated with one patient experiencing Grade 4 neutropenia.

ZAP Surgical Announces Upcoming Installation of Next-Generation ZAP-X Gyroscopic Radiosurgery in Ankara, Turkey

Retrieved on: 
Tuesday, September 26, 2023
Radiology, Biotechnology, Surgery, Oncology, Health, Medical Devices, Hospitals, Other Health, SRS, Hacettepe University, Trigeminal neuralgia, Breast, Uveal melanoma, Multimedia, Brain, Radiation therapy, Radiosurgery, Teaching hospital, Lung, Chiari malformation, Stereotactic surgery, Management of prostate cancer, AVM, Patient, ZAP, Isotope, Medical imaging

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Hacettepe University Hospital in Ankara, Turkey is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform before the end of the year.

Key Points: 
  • ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Hacettepe University Hospital in Ankara, Turkey is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform before the end of the year.
  • View the full release here: https://www.businesswire.com/news/home/20230926608561/en/
    ZAP-X Gyroscopic Radiosurgery platform.
  • For select indications, radiosurgery has proven to provide equivalent to superior outcomes compared to costly and potentially debilitating surgeries.
  • “With the addition of ZAP-X, they will further reinforce their reputation as global center of medical excellence.”

NCCN Releases Statement Addressing Ongoing Chemotherapy Shortages; Shares Survey Results Finding More than 90% of Cancer Centers are Impacted

Retrieved on: 
Wednesday, June 7, 2023
Database, Advocacy, U.S. federal government response to the COVID-19 pandemic, Cancer, Platinum, Breast, National Comprehensive Cancer Network, Cisplatin, Carboplatin, Journal of the National Comprehensive Cancer Network, Lung, NCCN, Federation, Pharmacist, Management of prostate cancer, MD, Patient, Lymphoma, MSW, Oncology, Nursing, Policy

PLYMOUTH MEETING, Pa., June 7, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading academic cancer centers—published survey results today that shed light on just how widespread the current platinum chemotherapy shortage is, and shared a statement calling on the whole oncology community to work together on solutions.

Key Points: 
  • 93% of cancer centers surveyed report a shortage of carboplatin and 70% report shortages for cisplatin.
  • The survey conducted by the NCCN Best Practices Committee features answers from 27 NCCN Member Institutions serving patients with cancer across the United States.
  • "These results demonstrate the widespread impact of the chemotherapy shortage," said Alyssa Schatz, MSW, Senior Director of Policy and Advocacy for NCCN.
  • Visit NCCN.org/platinum-statement to view the full statement and NCCN.org/platinum-survey for the survey results.

OncoNano Medicine Presents Positive Final Results from Phase 2 Trial of Pegsitacianine in Podium Presentation at 2023 ASCO Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023
Oncology, Health, Biometrics, Other Health, Clinical Trials, Pharmaceutical, Genotype, Surgeon, Histology, Neoplasm, EVP, American Society of Clinical Oncology, Cancer, Coronavirus Scientific Advisory Board, Breast, Head, Neck, ASCO, Phase 3, Management of prostate cancer, MD, Patient, TME, Society, Complex, Medical imaging

OncoNano Medicine, Inc. will present positive final results from its Phase 2 study of pegsitacianine, a pH-sensitive fluorescent nanoprobe for enhanced intra-operative visualization of cancer, in a podium presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023.

Key Points: 
  • OncoNano Medicine, Inc. will present positive final results from its Phase 2 study of pegsitacianine, a pH-sensitive fluorescent nanoprobe for enhanced intra-operative visualization of cancer, in a podium presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023.
  • Results of the study show that acidic pH is a viable marker and can be used for tumor targeting by the company’s ON-BOARD™ micelle platform.
  • Pegsitacianine has been studied in more than 135 patients across multiple tumor types, including peritoneal metastatic, breast, head and neck, colorectal, esophageal, ovarian and prostate cancers.
  • Results show that pegsitacianine is able to localize different tumor types regardless of their histology or anatomic location.

American Skin Association and the National Council for Skin Cancer Prevention Partner to Remind Americans to Enjoy the Sun Safely this Summer

Retrieved on: 
Friday, May 26, 2023
ASA, Radiation, Skin cancer, Cancer, Breast, Tanning, Snow, Lung, Colon, Organization, Management of prostate cancer, National Council, Risk, Water, Skin, Sand, Leather

This campaign stresses the importance of sun safety awareness and reminds everyone to protect their skin while enjoying the outdoors.

Key Points: 
  • This campaign stresses the importance of sun safety awareness and reminds everyone to protect their skin while enjoying the outdoors.
  • In fact, 1 out of every 5 Americans will be diagnosed with some form of skin cancer in their lifetime.
  • "We are proud to partner with the National Council on Skin Cancer Prevention and the other esteemed coalition members to get this life-saving message front and center."
  • Over 90% of all skin cancer is caused by exposure to ultraviolet radiation from the sun or indoor tanning devices.

CytoVeris Publishes Preclinical Study Showing Potential of its TumorMAP System for Cancer Detection

Retrieved on: 
Tuesday, February 7, 2023
Pathology, Woman, Standard of care, Breast cancer, Medical laboratory, Patient, Artificial intelligence, Immunohistochemistry, BCS, Associate, Marie Cassidy, Management of prostate cancer, Disease, Yale school, MD, Archives of Pathology & Laboratory Medicine, Yale School of Medicine, Breast, Surgeon, Cancer, Doctor of Philosophy, Medical imaging, Medicine

FARMINGTON, Conn., Feb. 7, 2023 /PRNewswire-PRWeb/ -- CytoVeris Inc., a medical device company developing AI-powered cancer imaging technologies to enable more precise surgical decision-making and improve patient outcomes, today announced the publication of preclinical data showing the potential of its TumorMAPTM system to detect cancer. The system is based on a proprietary Multi-Spectral Tissue Auto-Fluorescence Imaging (MS-TAFI) technology that analyzes the "optical fingerprint" of tissue and deciphers its intrinsic biomolecular and morphological characteristics without the use of dyes or imaging agents. The study is published in the peer-reviewed journal Archives of Pathology and Laboratory Medicine. This technology has the potential to evaluate resection margins intraoperatively during surgical procedures.

Key Points: 
  • FARMINGTON, Conn., Feb. 7, 2023 /PRNewswire-PRWeb/ -- CytoVeris Inc. , a medical device company developing AI-powered cancer imaging technologies to enable more precise surgical decision-making and improve patient outcomes, today announced the publication of preclinical data showing the potential of its TumorMAPTM system to detect cancer.
  • The study is published in the peer-reviewed journal Archives of Pathology and Laboratory Medicine.
  • This technology has the potential to evaluate resection margins intraoperatively during surgical procedures.
  • "This study demonstrates the potential for our technology to improve the precision of breast cancer resection, but we won't stop there.

Olympus Announces Launch of Olympus Asia Pacific Innovation Program

Retrieved on: 
Monday, December 5, 2022
Breast cancer, Quality of life, Management of prostate cancer, Laparoscopy, Health, Incidence, Colon, Medicine, Endoscopy, Lung, Stomach, Growth, Cancer, Military Medical Business, Automotive Supplier Innovation Program, Patient, Medtech, Medical imaging, Pharmaceutical industry, Online shopping, Dentistry, Medical device

As part of Olympus' dedication to continuing its history of innovation, Olympus is proud to announce the inaugural Olympus Asia Pacific Innovation Program (OAIP).

Key Points: 
  • As part of Olympus' dedication to continuing its history of innovation, Olympus is proud to announce the inaugural Olympus Asia Pacific Innovation Program (OAIP).
  • Olympus believes that the emergence of new technologies, particularly those within the digital realm, will revolutionize the patient care paradigm.
  • Felicia Chung, Olympus Business Development Leader for the Asia Pacific region said "I am pleased to announce Olympus' first-ever Innovation Program that seeks to identify and collaborate with innovators in the very exciting medtech space.
  • Marc Radatt, CEO for Olympus Corporation of Asia Pacific Limited and board member of the Asia Pacific Medical Technology Association (APACMed), said "Olympus is proud to have partnered with MedTech Innovator Asia Pacific in pursuit of new ideas that will revolutionize patient outcomes and increase access to new technologies through the OAIP.

Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022

Retrieved on: 
Wednesday, September 21, 2022
Safety, Breast, Trial of the century, Infection, COVID-19, Efficiency, Lotte New York Palace Hotel, AR, FDA, Tadalafil, CDK, Telehealth, Finasteride, Company, The New England Journal of Medicine, TGA, Medicines and Healthcare products Regulatory Agency, Review, Private Securities Litigation Reform Act, Gonadotropin-releasing hormone, COVID, Forward-looking statement, Capsule, Government, Patient, Pregnancy, U.S. Securities and Exchange Commission, Management of prostate cancer, Vaccine, European Medicines Agency, MHRA, Fast Track, NASDAQ, Insurance, Collection, Form 10-Q, Death, Security (finance), Conference, Zuclomifene, Prostate cancer, GLOBE, Lilly, Man, Eli Lilly and Company, Flash, Medicine, Pharmaceutical industry, Birth control, Medical imaging, Hematology

Veru is a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers.

Key Points: 
  • Veru is a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers.
  • The Company has completed a positive Phase 3 COVID-19 study evaluating sabizabulin in hospitalized moderate to severe COVID-19 patients at high risk for ARDS.
  • A double-blind, randomized, placebo-controlled Phase 3 COVID-19 clinical trial was conducted in 204 hospitalized COVID-19 patients with moderate to severe COVID at high risk for ARDS and death.
  • Verus late-stage prostate cancer portfolio comprises sabizabulin, VERU-100, a long-acting GnRH antagonist, and zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist.